Donna Headlee - Concepedia

Author

Donna Headlee

National Cancer Institute

Also Known As

D Headlee, D J Headlee, D. Headlee, D.J. Headlee, Donna Headlee, Donna J Headlee, Donna J. Headlee

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Center for Cancer Research National Institutes of Health Clinical Center National Cancer Institute

About

Donna Headlee is an author at National Cancer Institute specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	884
2	Business	1	1	42
3	Health Sciences	1	1	17
4	Allergy	1	1	120
5	Endocrinology	1	1	25

Donna Headlee

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Adrian M. Senderowicz, Donna Headlee, Sherman F. Stinson, Journal of Clinical Oncology	1998	408
Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma Qin Ryan, Donna Headlee, Milin Acharya, Journal of Clinical Oncology	2005	406
Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms Edward A. Sausville, Susan G. Arbuck, Richard A. Messmann, Journal of Clinical Oncology	2001	294
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Eiichi Fuse, Hiromi Tanii, Noriaki Kurata, PubMed Molecular PharmacologyAlpha1-acid GlycoproteinUnusual PharmacokineticsOncologyGlycosylation	1998	203
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study EA Sausville, Donna Headlee, M Stetler-Stevenson, Blood	1995	164
A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Alain Thibault, Michael R. Cooper, William D. Figg, PubMed Medicinal ChemistryPharmacological StudyMedicineTumor GrowthPharmacology	1994	157
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma MJ Stone, EA Sausville, JW Fay, Blood	1996	139
Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer Oliver Sartor, Michael R. Cooper, M. Weinberger, JNCI Journal of the National Cancer Institute	1994	138
Phase I study of phenylacetate administered twice daily to patients with cancer Alain Thibault, Dvorit Samid, Michael R. Cooper, Cancer	1995	129
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Richard A. Messmann, Ellen S. Vitetta, Donna Headlee, PubMed ImmunologyPathologyMetronomic ChemotherapyImmunotherapyOncology	2000	120

Page 1